Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.41 |
| ▸ | NPY1R | P25929 | 9/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.41 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | NRP1 | O14786 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533810 | 0.98 | NPY4R (0.44) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL29533919 | 0.94 | NPY5R (0.42) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL29414400 | 0.93 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29355526 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL3961412 | 0.89 | QRFPR (0.46) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL3961387 | 0.89 | QRFPR (0.46) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL29569172 | 0.89 | QRFPR (0.46) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL15757149 | 0.89 | C3AR1 (0.42) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL15757154 | 0.89 | C3AR1 (0.42) | NPY4RNPY1RNPY5RQRFPRNPY2R | |
| SCHEMBL6850341 | 0.89 | FURIN (0.40) | NPY4RNPY1RNPY5RQRFPRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | PAUL SCHERRER INSTITUT (CH) | 2022-05-05 | — | — | US | disclosed |
| EP-3941526-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | Paul Scherrer Institut (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | TGM3, TGM2, GLUL | NPY4R 2474/4885NPY1R 2136/4885NPY5R 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.